A5000921376- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Immunodeficiency and Autoimmune Disorders
- Acute Lymphoblastic Leukemia research
- Monoclonal and Polyclonal Antibodies Research
- Histone Deacetylase Inhibitors Research
- Advanced Breast Cancer Therapies
- Protein Degradation and Inhibitors
- Immune Cell Function and Interaction
- Multiple Myeloma Research and Treatments
- PI3K/AKT/mTOR signaling in cancer
- Galectins and Cancer Biology
- CAR-T cell therapy research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Glycosylation and Glycoproteins Research
- Cancer-related Molecular Pathways
- Epigenetics and DNA Methylation
- Ubiquitin and proteasome pathways
- Phagocytosis and Immune Regulation
- Cancer-related gene regulation
- Gastrointestinal Tumor Research and Treatment
- Advanced biosensing and bioanalysis techniques
University of Cincinnati
2021-2025
The Ohio State University
2015-2024
University of Cincinnati Medical Center
2021-2024
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
2012-2023
The Ohio State University Wexner Medical Center
2013-2022
Sylvester Comprehensive Cancer Center
2005-2022
Ohio University
2012-2022
American Association of Colleges of Pharmacy
2007-2021
Comprehensive Blood & Cancer Center
2005-2021
Cancer Institute (WIA)
2019
Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and effective in chronic lymphocytic leukemia (CLL). Resistance to inhibitors resistance associated with BTK inhibition have not been characterized. Although only a small proportion patients had relapse during ibrutinib therapy, understanding mechanisms important. We evaluated relapsed disease identify mutations that may mediate resistance.
The most common human leukemia is B cell chronic lymphocytic (CLL), a malignancy of mature cells with characteristic clinical presentation but variable course. rearranged immunoglobulin (Ig) genes CLL may be either germ-line in sequence or somatically mutated. Lack Ig mutations defined distinctly worse prognostic group patients raising the possibility that comprises two distinct diseases. Using genomic-scale gene expression profiling, we show characterized by "signature," irrespective...
Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment chronic lymphocytic leukemia (CLL). However, also irreversibly inhibits alternative targets, which potentially compromises its index. Acalabrutinib (ACP-196) is a more selective, irreversible BTK inhibitor that specifically designed to improve on safety and efficacy first-generation inhibitors.In this uncontrolled, phase 1-2, multicenter study, we administered...
Purpose We evaluated the safety and feasibility of anti-CD19 chimeric antigen receptor-modified T (CAR-T) cell therapy in patients with chronic lymphocytic leukemia (CLL) who had previously received ibrutinib. Methods Twenty-four CLL lymphodepleting chemotherapy CAR-T cells at one three dose levels (2 × 105, 2 106, or 107 cells/kg). Nineteen experienced disease progression while receiving ibrutinib, were ibrutinib intolerant, two did not experience Six venetoclax refractory, 23 a complex...
Cancer is associated with immune deficiency, but the biologic basis of this poorly defined. Here we demonstrate that impaired actin polymerization results in CD4+ and CD8+ T cells from patients chronic lymphocytic leukemia (CLL) exhibiting defective immunological synapse formation APCs. Although dysfunction was part a result CLL having poor APC function, also identified CLL. We further that, following contact cells, defects were induced healthy allogeneic cells. This required direct...
<h3>Importance</h3> The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is effective in patients with chronic lymphocytic leukemia (CLL). Reasons for discontinuing therapy this drug and outcomes following discontinuation have not been evaluated outside of clinical trials relatively short follow-up. <h3>Objective</h3> To determine features associated outcomes. <h3>Design, Setting, Participants</h3> A total 308 participating 4 sequential at Ohio State University Comprehensive Cancer Center...
Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We conducted an open-label, randomized, noninferiority, phase III trial comparing and ibrutinib in patients with chronic lymphocytic leukemia (CLL).
A phase II clinical trial with single-agent decitabine was conducted in older patients (≥60 years) previously untreated acute myeloid leukemia (AML) who were not candidates for or refused intensive chemotherapy. Subjects received low-dose at 20 mg/m 2 i.v. over 1 h on days to 10. Fifty-three subjects enrolled a median age of 74 years (range, 60–85). Nineteen (36%) had antecedent hematologic disorder therapy-related AML; 16 complex karyotypes (≥3 abnormalities). The complete remission rate...
Purpose Therapeutic targeting of Bruton tyrosine kinase (BTK) with ibrutinib in chronic lymphocytic leukemia has led to a paradigm shift therapy, and relapse been uncommon current follow-up. Acquired mutations BTK PLCG2 can cause relapse, but data regarding the prevalence natural history these are limited. Patients Methods accrued four sequential studies were included analyses. Deep sequencing for was performed retrospectively on patients who experienced prospectively screening population....
Abstract Ibrutinib, a once‐daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United States and Europe for treatment patients with chronic lymphocytic leukemia (CLL) or small lymphoma (SLL). The phase 3 RESONATE study showed improved efficacy single‐agent ibrutinib over ofatumumab relapsed/refractory CLL/SLL, including those high‐risk features. Here we report final analysis from median follow‐up on 65.3 months (range, 0.3‐71.6) arm. Median progression‐free survival (PFS)...